keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/29689599/role-of-metastasis-directed-treatment-in-kidney-cancer
#1
REVIEW
Sarah P Psutka, Viraj A Master
Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive with systemic therapy alone. Definitive treatment of the metastatic deposit remains the sole potentially curative option and is a cornerstone of mRCC therapy, offering potential for both local control and palliation of tumor-related symptoms. In this review, the evidence supporting the definitive treatment of mRCC is examined and summarized, including the use of surgical metastasectomy, thermal ablation, radiotherapy, and other minimally invasive options...
April 24, 2018: Cancer
https://www.readbyqxmd.com/read/29687160/evaluation-of-relative-dose-intensity-during-the-early-phase-of-first-line-sunitinib-treatment-using-a-2-week-on-1-week-off-regimen-for-metastatic-renal-cell-carcinoma
#2
Kana Iwamoto, Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Kazuhiko Yoshida, Junpei Iizuka, Kazunari Tanabe
Sunitinib treatment with a 2-week-on/1-week-off schedule (Schedule 2/1) is a common alternative regimen with high relative dose intensity (RDI) and superior tolerability for patients with metastatic renal cell carcinoma (mRCC). The prognostic impact of RDI is reported only in 4-week-on/2-week-off or mixed regimens. Herein, we evaluated the prognostic impact of RDI during early-phase sunitinib treatment using Schedule 2/1. Seventy-four patients who received first-line sunitinib treatment using Schedule 2/1 were evaluated...
April 23, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29678472/prognostic-value-of-baseline-serum-c-reactive-protein-level-in-intermediate-risk-group-patients-with-metastatic-renal-cell-carcinoma-treated-by-first-line-vascular-endothelial-growth-factor-targeted-therapy
#3
Kimiharu Takamatsu, Ryuichi Mizuno, Minami Omura, Shinya Morita, Kazuhiro Matsumoto, Kazunobu Shinoda, Takeo Kosaka, Toshikazu Takeda, Toshiaki Shinojima, Eiji Kikuchi, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
BACKGROUND: Almost half of patients with metastatic renal-cell carcinoma (mRCC) are classified as intermediate risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The aim of this study was to evaluate whether baseline C-reactive protein (CRP) levels predict overall survival (OS) in intermediate-risk group mRCC patients. PATIENTS AND METHODS: Data from 107 intermediate-risk group mRCC patients receiving first-line targeted therapy were retrospectively reviewed...
March 27, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29662544/sunitinib-in-the-treatment-of-renal-cell-carcinoma-an-update-on-recent-evidence
#4
REVIEW
Mimma Rizzo, Camillo Porta
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to use sunitinib...
August 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29656851/first-line-systemic-therapy-for-metastatic-renal-cell-carcinoma-a-systematic-review-and-network-meta-analysis
#5
REVIEW
Christopher J D Wallis, Zachary Klaassen, Bimal Bhindi, Xiang Y Ye, Thenappan Chandrasekar, Ann M Farrell, Hanan Goldberg, Stephen A Boorjian, Bradley Leibovich, Girish S Kulkarni, Prakesh S Shah, Georg A Bjarnason, Daniel Heng, Raj Satkunasivam, Antonio Finelli
CONTEXT: In the last decade, there has been a proliferation of treatment options for metastatic renal cell carcinoma (mRCC). However, direct comparative data are lacking for most of these agents. OBJECTIVE: To indirectly compare the efficacy and safety of systemic therapies used in the first-line treatment of mRCC. EVIDENCE ACQUISITION: Medline, EMBASE, Web of Science, and Scopus databases were searched using the OvidSP platform for studies indexed from database inception to October 23, 2017...
April 13, 2018: European Urology
https://www.readbyqxmd.com/read/29650037/open-label-randomized-multicentre-phase-ii-study-to-assess-the-efficacy-and-tolerability-of-sunitinib-by-dose-administration-regimen-dose-modification-or-dose-interruptions-in-patients-with-advanced-or-metastatic-renal-cell-carcinoma-study-protocol-of-the-surf
#6
Guillaume Mouillet, Marie-Justine Paillard, Tristan Maurina, Dewi Vernerey, Thierry Nguyen Tan Hon, Hamadi Almotlak, Ulrich Stein, Fabien Calcagno, Diane Berthod, Elise Robert, Aurelia Meurisse, Antoine Thiery-Vuillemin
BACKGROUND: Sunitinib is a tyrosine kinase inhibitor approved in the first-line metastatic renal cell carcinoma (MRCC) setting at the dose of 50 mg daily for 4 weeks followed by a pause of 2 weeks. Due to toxicity, this standard schedule (50 mg daily 4/2) can induce up to 50% of sunitinib dose modification (reduction and/or interruption). The current recommendation in such case is to reduce the dose to 37.5 mg per day (standard schedule 4/2). Recent data highlight an alternative schedule: 2 weeks of treatment followed by 1 week of pause (experimental schedule 2/1)...
April 12, 2018: Trials
https://www.readbyqxmd.com/read/29607820/assessment-of-sunitinib-alternative-prescription-schedules-in-metastatic-kidney-cancer-a-study-of-10-cases
#7
Habib Diallo, Hasnae Alaoui Mhamdi, Salma Elouarzazi, Mohamed Fadli, Rhizlane Belbaraka
BACKGROUND: Managing metastatic Renal Cell Carcinoma (mRCC) has been revolutionized during the first decade of the 21st century due to the development of targeted therapies. The sunitinib is an oral multi-targeted receptor Tyrosine Kinase Inhibitor (TKI). It became the first targeted therapy as first-line treatment to improve the survival of patients with metastatic kidney cancer. This treatment consists in the oral intake of 50 mg of sunitinib per day in a 6 -week cycle including 4 weeks of treatment intake (the "on" week) followed by a 2-week break (the off week)...
January 2018: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/29600976/impact-of-endostatin-gene-therapy-on-myeloid-derived-suppressor-cells-from-a-metastatic-renal-cell-carcinoma
#8
K C Chaves, E M Costa, L F Teixeira, M H Bellini
AIM: To evaluate the role of endostatin (ES) gene therapy on myeloid-derived suppressor cells (MDSC) in a metastatic model of renal cell carcinoma (RCC). MATERIALS AND METHODS: Balb/C mice bearing orthotopic Renca tumors were treated with NIH/3T3-LendSN or, as a control, with NIH/3T3-LXSN cells. At the end of in vivo experiment, plasma and tissue lung samples were collected. Plasma ES and granulocyte colony stimulating factor (G-CSF) levels were measured by ELISA and Milliplex, respectively...
March 2018: Experimental Oncology
https://www.readbyqxmd.com/read/29587324/-immunotherapy-for-renal-cell-carcinoma-current-status
#9
Marc-Oliver Grimm, Susan Foller
Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo® ) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs...
April 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29578848/the-additional-costs-per-month-of-progression-free-survival-and-overall-survival-an-economic-model-comparing-everolimus-with-cabozantinib-nivolumab-and-axitinib-for-second-line-treatment-of-metastatic-renal-cell-carcinoma
#10
Elyse Swallow, Andrew Messali, Sameer Ghate, Evangeline McDonald, Emilie Duchesneau, Jose Ricardo Perez
BACKGROUND: When considering optimal second-line treatments for metastatic renal cell carcinoma (mRCC), clinicians and payers seek to understand the relative clinical benefits and costs of treatment. OBJECTIVE: To use an economic model to compare the additional cost per month of overall survival (OS) and of progression-free survival (PFS) for cabozantinib, nivolumab, and axitinib with everolimus for the second-line treatment of mRCC from a third-party U.S. payer perspective...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29575038/hospital-volume-and-short-term-outcomes-after-cytoreductive-nephrectomy
#11
Leilei Xia, Marshall C Strother, Benjamin L Taylor, Raju R Chelluri, Jose E Pulido, Thomas J Guzzo
PURPOSE: To investigate the impact of hospital volume on short-term outcomes after cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). METHODS: We identified mRCC patients who underwent CN from 2006 to 2013 in the National Cancer Database. Annual hospital CN volume was categorized as high (top 20th percentile) and low. Multivariable logistic regressions were used to compare 30-day mortality, 90-day mortality, prolonged length of stay (PLOS, ≥7 days), and 30-day readmission rates...
March 25, 2018: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29574109/comparative-survival-following-initial-cytoreductive-nephrectomy-versus-initial-targeted-therapy-for-metastatic-renal-cell-carcinoma
#12
Bimal Bhindi, Elizabeth B Habermann, Ross J Mason, Brian A Costello, Lance C Pagliaro, R Houston Thompson, Bradley C Leibovich, Stephen A Boorjian
PURPOSE: The optimal sequence of cytoreductive nephrectomy (CN) and targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) is unclear. We sought to compare overall survival (OS) between patients with mRCC receiving initial CN (iCN) with or without subsequent TT versus initial TT (iTT) with or without subsequent CN. METHODS: Patients in the National Cancer Database diagnosed between 2006-2013 with metastatic RCC and who received CN, TT, or both were evaluated...
March 21, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29570259/prognostic-significance-of-the-dynamic-changes-of-systemic-inflammatory-response-in-metastatic-renal-cell-carcinoma
#13
Beihe Wang, Weijie Gu, Fangning Wan, Guohai Shi, Dingwei Ye
PURPOSE: To elucidate the prognostic value of systemic inflammatory response in patients with metastatic renal cell carcinoma (mRCC) who are treated with sunitinib, we evaluated the prognostic role of C-reactive protein (CRP) kinetics. This study also compared prognostic models containing CRP kinetics and neutrophil-to-lymphocyte ratio (NLR) kinetics. MATERIALS AND METHODS: A consecutive cohort of 94 patients with mRCC who were treated with sunitinib was retrospectively included from Fudan University Shanghai Cancer Center...
March 23, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
https://www.readbyqxmd.com/read/29569164/prognostic-and-predictive-factors-for-renal-cell-carcinoma
#14
Cristina Suárez, Marc Campayo, Romà Bastús, Sergi Castillo, Olatz Etxanitz, Marta Guix, Núria Sala, Enrique Gallardo
Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit...
March 22, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29563746/metastatic-renal-cell-cancer-systemic-therapy
#15
Amit Joshi, Arvind Sahu, Vanita Noronha, Vijay Patil, Kumar Prabhash
Management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the past 10 years due to better understanding of tumor biology. This development has changed mRCC to a chronic progressive disease with several lines of treatment options. The introduction of several new targeted therapies including immunotherapy has improved median overall survival of approximately 1 year to >2 years in mRCC.
March 2018: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29563634/the-tyrosine-kinase-inhibitor-sunitinib-targets-vascular-endothelial-ve-cadherin-a-marker-of-response-to-antitumoural-treatment-in-metastatic-renal-cell-carcinoma
#16
Helena Polena, Julie Creuzet, Maeva Dufies, Adama Sidibé, Abir Khalil-Mgharbel, Aude Salomon, Alban Deroux, Jean-Louis Quesada, Caroline Roelants, Odile Filhol, Claude Cochet, Ellen Blanc, Céline Ferlay-Segura, Delphine Borchiellini, Jean-Marc Ferrero, Bernard Escudier, Sylvie Négrier, Gilles Pages, Isabelle Vilgrain
BACKGROUND: Vascular endothelial (VE)-cadherin is an endothelial cell-specific protein responsible for endothelium integrity. Its adhesive properties are regulated by post-translational processing, such as tyrosine phosphorylation at site Y685 in its cytoplasmic domain, and cleavage of its extracellular domain (sVE). In hormone-refractory metastatic breast cancer, we recently demonstrated that sVE levels correlate to poor survival. In the present study, we determine whether kidney cancer therapies had an effect on VE-cadherin structural modifications and their clinical interest to monitor patient outcome...
March 22, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29558966/a-prospective-phase-i-dose-escalation-trial-of-stereotactic-ablative-radiotherapy-sabr-as-an-alternative-to-cytoreductive-nephrectomy-for-inoperable-patients-with-metastatic-renal-cell-carcinoma
#17
Rohann J M Correa, Belal Ahmad, Andrew Warner, Craig Johnson, Mary J MacKenzie, Stephen E Pautler, Glenn S Bauman, George B Rodrigues, Alexander V Louie
BACKGROUND: Cytoreductive nephrectomy is thought to improve survival in metastatic renal cell carcinoma (mRCC). As many patients are ineligible for major surgery, we hypothesized that SABR could be a safe alternative. METHODS: In this dose-escalation trial, inoperable mRCC patients underwent SABR targeting the entire affected kidney. Toxicity (CTCAE v3.0), quality of life (QoL), renal function, and tumour response (RECIST v1.0) were assessed. RESULTS: Twelve patients of mostly intermediate (67%) or poor (25%) International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic class, median KPS of 70%, and median tumour size of 8...
March 20, 2018: Radiation Oncology
https://www.readbyqxmd.com/read/29554654/radiotherapy-and-vascular-endothelial-growth-factor-receptor-tyrosine-kinase-inhibitors-in-renal-cancer
#18
Michele Fiore, Rolando Maria D Apos Angelillo, Carlo Greco, Iacopo Fioroni, Edy Ippolito, Daniele Santini, Sara Ramella
Treatment of metastatic renal cell carcinoma (mRCC) has seen substantial progress over the last decade. A number of targeted therapies have been shown to improve clinical outcome. Vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) are an effective option in treating mRCC. RCC is traditionally perceived to be a radioresistant malignancy with a limited role of radiotherapy (RT) in the management of localized disease. While RCC appears to be radioresistant using conventionally fractionated RT, preclinical data suggest increased radiosensitivity when an ablative, hypofractionated schedule is used...
March 19, 2018: Chemotherapy
https://www.readbyqxmd.com/read/29551901/a-national-multicenter-non-interventional-observational-study-on-treatment-patterns-in-patients-with-metastatic-renal-cell-carcinoma-in-turkey-notes-study
#19
Şuayib Yalçın, Ramazan Yildiz, Faysal Dane, Aziz Karaoğlu, Berna Öksüzoğlu, Özgür Özyılkan, Alper Sevinç, Feyyaz Özdemir, Hande Turna, Rüçhan Uslu, Esat Ulay
Introduction: The introduction of targeted therapies in renal cell carcinoma has significantly improved its prognosis and treatment outcomes in recent years. Such treatment options are targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mammalian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing information on the use of everolimus only after initial interferon and second-line VEGF-targeted treatments such as VEGF-TKI...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29534940/nivolumab-is-a-cost-effective-second-line-treatment-for-metastatic-renal-cell-carcinoma
#20
Jacopo Giuliani, Andrea Bonetti
INTRODUCTION: The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represented by the improvement of the clinical parameters of interest such as progression-free survival (PFS) and overall survival (OS). METHODS: This analysis was conducted to assess the pharmacologic costs of second-line treatments for mRCC and was restricted to pivotal phase 3 randomized controlled trials (RCTs) used as second-line therapy...
February 22, 2018: Clinical Genitourinary Cancer
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"